Literature DB >> 26383007

Saving life and brain with extracorporeal cardiopulmonary resuscitation: A single-center analysis of in-hospital cardiac arrests.

Graham Peigh1, Nicholas Cavarocchi1, Hitoshi Hirose2.   

Abstract

OBJECTIVE: Despite advances in medical care, survival to discharge and full neurologic recovery after cardiac arrest remains less than 20% after cardiopulmonary resuscitation. An alternate approach to traditional cardiopulmonary resuscitation is extracorporeal cardiopulmonary resuscitation, which places patients on extracorporeal membrane oxygenation during cardiopulmonary resuscitation and provides immediate cardiopulmonary support when traditional resuscitation has been unsuccessful. We report the results from extracorporeal cardiopulmonary resuscitation at the Thomas Jefferson University.
METHODS: Between 2010 and June 2014, 107 adult extracorporeal membrane oxygenation procedures were performed at the Thomas Jefferson University. Patient demographics, survival to discharge, and neurologic recovery of patients who underwent extracorporeal cardiopulmonary resuscitation were retrospectively analyzed with institutional review board approval.
RESULTS: A total of 23 patients (15 male and 8 female; mean age, 46 ± 12 years) underwent extracorporeal cardiopulmonary resuscitation. All patients who met criteria were placed on 24-hour hypothermia protocol (target temperature 33°C) with initiation of extracorporeal membrane oxygenation. The mean duration of extracorporeal membrane oxygenation support was 6.2 ± 5.5 days. Nine patients died while on extracorporeal membrane oxygenation from the following causes: anoxic brain injury (4), stroke (4), and bowel necrosis (1). Two patients with anoxic brain injury on extracorporeal cardiopulmonary resuscitation donated multiple organs for transplant. The survival to discharge was 30% (7/23 patients) with approximately 100% full neurologic recovery.
CONCLUSIONS: The extracorporeal cardiopulmonary resuscitation procedure provided reasonable patient recovery. Extracorporeal cardiopulmonary resuscitation also allowed for neurologic recovery and made multiorgan procurement possible. On the basis of the survival, extracorporeal cardiopulmonary resuscitation should be considered when determining the optimal treatment path for patients who need cardiopulmonary resuscitation. The proper use of extracorporeal cardiopulmonary resuscitation improved the hospital outcomes for patients with in-hospital cardiac arrest.
Copyright © 2015 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiopulmonary resuscitation; extracorporeal membrane oxygenation; resuscitation; survival

Mesh:

Year:  2015        PMID: 26383007     DOI: 10.1016/j.jtcvs.2015.07.061

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  5 in total

1.  Neurological complications during veno-venous extracorporeal membrane oxygenation.

Authors:  Hitoshi Hirose; Nicholas C Cavarocchi
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

Review 2.  Extracorporeal cardiopulmonary resuscitation for adults with shock-refractory cardiac arrest.

Authors:  Dennis Miraglia; Jonathan E Ayala
Journal:  J Am Coll Emerg Physicians Open       Date:  2021-01-18

3.  Extracorporeal Membrane Oxygenation for Cardiac Indications in Adults: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2020-03-06

Review 4.  A systematic review of current ECPR protocols. A step towards standardisation.

Authors:  't Joncke Koen; Thelinge Nathanaël; Dewolf Philippe
Journal:  Resusc Plus       Date:  2020-07-19

5.  Neurological outcome after extracorporeal cardiopulmonary resuscitation for in-hospital cardiac arrest: a systematic review and meta-analysis.

Authors:  Benjamin Yaël Gravesteijn; Marc Schluep; Maksud Disli; Prakriti Garkhail; Dinis Dos Reis Miranda; Robert-Jan Stolker; Henrik Endeman; Sanne Elisabeth Hoeks
Journal:  Crit Care       Date:  2020-08-17       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.